Truist Financial analyst Richard Newitter maintained a Buy rating on PROCEPT BioRobotics (PRCT – Research Report) yesterday and set a price target of $55.00. The company’s shares closed yesterday at $47.37.
According to TipRanks, Newitter is a 5-star analyst with an average return of 17.3% and a 59.89% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Stryker, Nevro Corp, and Inspire Medical Systems.
PROCEPT BioRobotics has an analyst consensus of Strong Buy, with a price target consensus of $51.71, which is a 9.16% upside from current levels. In a report released on January 16, Piper Sandler also assigned a Buy rating to the stock with a $58.00 price target.
See the top stocks recommended by analysts >>
PRCT market cap is currently $2.45B and has a P/E ratio of -20.78.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PROCEPT BioRobotics (PRCT) Company Description:
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
Read More on PRCT:
- Procept BioRobotics price target raised to $58 from $42 at Piper Sandler
- Procept BioRobotics price target raised to $47 from $44 at Wells Fargo
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
- Procept BioRobotics sees FY23 revenue $135.9M-$136.2M, consensus $133.51M
- Procept BioRobotics sees Q4 revenue $43.3M-$43.6M, consensus $40.91M
